DAWN (STOCKS)
Day One Biopharmaceuticals, Inc. Common Stock
$21.450000
-0.020000 (-0.09%)
Prev close: $21.470000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Jeremy Bender
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,218.32M
- Employees
- 181
- P/E (TTM)
- -20.62
- P/B (TTM)
- 5.01
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
0
Strong Buy
0
Buy
10
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.21 | $-0.15 | -0.0551 | -35.57% |
|
Sep 2025 (Q3)
|
$-0.19 | $-0.30 | +0.1086 | +36.37% |
|
Jun 2025 (Q2)
|
$-0.29 | $-0.36 | +0.0740 | +20.33% |
|
Mar 2025 (Q1)
|
$-0.35 | $-0.45 | +0.1014 | +22.46% |
Financial Statements
| Revenues | $158.18M |
| Benefits Costs and Expenses | $0.00 |
| Costs And Expenses | $285.93M |
| Nonoperating Income/Loss | $18.45M |
| Operating Expenses | $285.93M |
| Research and Development | $148.14M |
| Other Operating Expenses | $137.80M |
| Operating Income/Loss | -$127.75M |
| Income/Loss From Continuing Operations After Tax | -$107.32M |
| Income/Loss From Continuing Operations Before Tax | $158.18M |
| Income Tax Expense/Benefit | -$1.98M |
| Income Tax Expense/Benefit, Current | $1.98M |
| Income Tax Expense/Benefit, Deferred | $0.00 |
| Net Income/Loss | -$107.32M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$107.32M |
| Net Income/Loss Available To Common Stockholders, Basic | -$107.32M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.04 |
| Diluted Earnings Per Share | -$1.04 |
| Basic Average Shares | 103,205,703 |
| Diluted Average Shares | 103,205,703 |
| Assets | $507.83M |
| Current Assets | $485.10M |
| Accounts Receivable | $26.74M |
| Inventory | $6.33M |
| Other Current Assets | $452.04M |
| Noncurrent Assets | $22.73M |
| Fixed Assets | $2.14M |
| Other Non-current Assets | $20.59M |
| Liabilities | $66.67M |
| Current Liabilities | $60.52M |
| Accounts Payable | $3.73M |
| Other Current Liabilities | $56.79M |
| Noncurrent Liabilities | $6.14M |
| Equity | $441.16M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $441.16M |
| Liabilities And Equity | $507.83M |
| Net Cash Flow From Operating Activities | -$103.76M |
| Net Cash Flow From Operating Activities, Continuing | -$103.76M |
| Net Cash Flow From Investing Activities | $174.65M |
| Net Cash Flow From Investing Activities, Continuing | $174.65M |
| Net Cash Flow From Financing Activities | $1.22M |
| Net Cash Flow From Financing Activities, Continuing | $1.22M |
| Net Cash Flow | $72.11M |
| Net Cash Flow, Continuing | $72.11M |
| Comprehensive Income/Loss | -$107.34M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$107.34M |
| Other Comprehensive Income/Loss | -$107.34M |